Photocure Partner Asieris announces Approval to conduct a Phase III Clinical Trial for Hexvix in China
Oslo, Norway, February 11, 2022: Photocure ASA (PHO: OSE), The Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has obtained the Phase III clinical trial application (CTA) approval from the National Medical Products Administration (NMPA) of China for Hexvix[®].The study is a prospective, multicenter bridging trial aimed to investigate the additional detection rate and safety of Hexvix[®] and blue light cystoscopy (BLC[®]) versus white light cystoscopy in Chinese patients with non-muscle invasive bladder cancer (NMIBC, tumor types CIS, Ta, T1). The